Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday.
Mid-Day Market Update: Crude Oil Tumbles Over 6%; Nkarta Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday.
Why Nkarta Stock Is Soaring Today
Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.
Nkarta Presents New Preclinical Data From Engineered NK Cell Platform At AACR Annual Meeting 2022
Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural
42 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022.
HC Wainwright & Co. Initiates Coverage On Nkarta with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $25.